Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Bumann

Undersea and Hyperbaric Medicine Abilene, TX Doctor of Osteopathy

NPI 1306934435 CMS profile 104272

6250 Antilley Rd, Abilene Regional Wound Care Center, Abilene, TX 79606

Open in the dashboard

General payments

$153,565

521 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Bumann of Abilene, TX is reported in the CMS Open Payments database as having received $153,565 across 521 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,416 29
2024 General $792 28
2023 General $14,680 59
2022 General $13,187 40
2021 General $22,191 83
2020 General $27,827 83
2019 General $72,472 199

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Bumann
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Timothy Bumann were reported at $2,416. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.

Show as a table
Year Timothy Bumann Undersea and Hyperbaric Medicine median Middle half National median
2019 $72,472 $162 $85–$376 $163
2020 $27,827 $111 $46–$307 $114
2021 $22,191 $154 $50–$306 $132
2022 $13,187 $122 $40–$378 $149
2023 $14,680 $145 $52–$410 $160
2024 $792 $146 $80–$316 $164
2025 $2,416 $153 $68–$340 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $142,264 321 payments
  2. Tactile Systems Technology Inc $7,203 97 payments
  3. Kerecis Limited $2,368 13 payments
  4. Cashflow Solutions, LLC $561 37 payments
  5. AbbVie, Inc. $406 17 payments
  6. Smith+Nephew, Inc. $175 10 payments
  7. Urgo Medical North America, LLC $152 3 payments
  8. ConvaTec Inc. $113 6 payments
  9. KCI USA, Inc $100 5 payments
  10. Molnlycke Health Care US, LLC $57 3 payments
  11. Other $166 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $92,755 152 payments
  2. Honoraria $22,050 9 payments
  3. Consulting Fee $18,425 8 payments
  4. Travel and Lodging $12,383 88 payments
  5. Food and Beverage $7,852 263 payments
  6. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. Apligraf $71,623 154 payments
  2. Puraply/Affinity/NuTech $71,623 154 payments
  3. Dermagraft $71,623 154 payments
  4. Puraply $33,933 75 payments
  5. Puraply Antimicrobial $18,956 39 payments
  6. Affinity $14,824 28 payments
  7. ENTRE $6,129 49 payments
  8. ACTITOUCH $6,129 49 payments
  9. FLEXITOUCH $6,129 49 payments
  10. NuShield $2,239 9 payments
  11. Other $18,183 376 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

58

Median for Emergency Medicine: 88

Drug cost

$400

Median for Emergency Medicine: $590

Branded share of claims

20.7%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 21 $185
Ciprofloxacin Hcl Generic 14 $124
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $51
Levofloxacin Generic 11 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$3,382,381

Of which drugs: $2,642,075

Medicare patients

450

Average age 75

Services billed

7,430

213 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 60%
Ischemic heart disease 54%
Heart failure 47%
Chronic kidney disease 45%
Atrial fibrillation 40%
Depression 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Helicoll, per square centimeter Q4164 Office 20 1,496 $1,708,419

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $58
$58 — —
TEFLARO
  • AbbVie, Inc. $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

521 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record